Pfizer cancer research

Cancer Therapeutics CRC (CTx) brokered a multi-million dollar deal to the global pharmaceutical firm Pfizer that is underpinned by research carried out at the Monash Institute of Pharmaceutical Sciences (MIPS). CTx announced a two-year research collaboration and licence deal that includes advanced molecules that may hold the key to promising new drug developments. Dr Paul Stupple leads the medicinal chemistry efforts for CTx and is based at MIPS in Parkville.
Converting the small molecules that have been identified could be a game-changer in the way cancer is treated in the future; however this is a long-term project that could take up to 10 years before patients receive the benefit of this new approach.